Many valuable drugs do not possess the appropriate chemical and/or physical properties to be efficiently formulated and delivered to sites of disease.

Integrated Nanotherapeutics (INT) is a preclinical stage biotech company in Vancouver, Canada. Their proprietary drug delivery technology can deliver any type of drug modality in lipid nanoparticles (LNPs), either alone or in combination, to disease cells and tissues.

INT is advancing a first-in-class therapeutic program for autoimmune diseases. In addition, the company is partnering with various groups to develop novel LNP-based therapeutics for cancers and infectious diseases.